Rachel M Koldej

11PUBLICATIONS
67CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Dec 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.

Sasanka M Handunnetti, Amit Khot, Piers Blombery

|Jan 24, 2025
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.

Allison Barraclough, Sze Ting Lee, Melinda Burgess

|Oct 29, 2024
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia.

Meng-Xiao Luo, Tania Tan, Marie Trussart

|Apr 25, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.

Sasanka M Handunnetti, Mary Ann Anderson, Kate Burbury

|Oct 26, 2023
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.

Adrian Minson, Nada Hamad, Chan Y Cheah

|Jan 13, 2023
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.

Lavinia Tan, Ben Tran, Jeanne Tie

Pageof 2

Frequent Collaborators

6 joint publications

David S Ritchie

3 joint publications

Ashvind Prabahran

3 joint publications

Stephen Lade

3 joint publications

John F Seymour